Dr. Hock is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Fruit St
# Hematolo
Boston, MA 02114Phone+1 617-724-4000Fax+1 617-726-2894
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1996 - 1999
Icahn School of Medicine at Mount Sinai/Beth IsraelResidency, Internal Medicine, 1993 - 1996
Freie University Berlin Faculty of MedicineClass of 1989
Certifications & Licensure
MA State Medical License 1996 - 2025- American Board of Internal Medicine Hematology
Clinical Trials
- ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML Start of enrollment: 2018 Jul 24
Publications & Presentations
PubMed
- 113 citationsETV6-NTRK3 fusion oncogene initiates breast cancer from committed mammary progenitors via activation of AP1 complex.Zhe Li, Cristina E. Tognon, Frank J. Godinho, Laura Yasaitis, Hanno Hock
Cancer Cell. 2007-12-06 - 81 citationsTEL-AML1 Corrupts Hematopoietic Stem Cells to Persist in the Bone Marrow and Initiate LeukemiaJeffrey W. Schindler, Denille Van Buren, Adlen Foudi, Ondrej Krejci, Jinzhong Qin
Cell Stem Cell. 2009-07-02 - 82 citationsETV6 in hematopoiesis and leukemia predisposition.Hanno Hock, Akiko Shimamura
Seminars in Hematology. 2017-04-01
Press Mentions
MGH Study Identifies First Molecular Steps to Childhood LeukemiaJuly 15th, 2009- Some Blood-System Stem Cells Reproduce More Slowly Than ExpectedDecember 5th, 2008
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
